Revvity Inc. has announced the launch of multiple new discovery platforms and technologies at SLAS2026 to accelerate high-throughput drug discovery workflows. The company's new products include the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation. These innovations are aimed at enhancing lab automation, detection, and imaging capabilities, supporting discovery programs from early screening to data-driven decision making. Revvity’s latest launches reflect its commitment to advancing laboratory technology and supporting the evolving needs of drug discovery labs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.